Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC

December 21st 2022

The European Commission has approved the combination of olaparib plus abiraterone acetate and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

Dr. Mian on the Investigation into the Synchronous Up-front Setting of Metastatic Prostate Cancer

December 19th 2022

Omar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.

Interpreting Data From the CARD Trial in Metastatic CRPC

December 19th 2022

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, review data from the CARD trial and discuss the nuanced selection and sequencing of treatment in metastatic CRPC.

The PROSELICA Trial: Cabazitaxel Dosing in Metastatic CRPC

December 19th 2022

Expert perspectives on the PROSELICA trial, which helped inform optimal dosing strategies with cabazitaxel in metastatic castration-resistant prostate cancer.

An Economic Evaluation of Cabazitaxel Versus a Second Androgen Receptor‑targeted Agent (ARTA) for Patients with Metastatic Castration‑resistant Prostate Cancer Previously Treated with Docetaxel and an ARTA: the United States Payer Perspective

December 16th 2022

Dr Thomas Hutson reviews recently published data on patient outcomes and estimated healthcare costs associated with use of third-line cabazitaxel versus a second ARTA in patients with metastatic castration-resistant prostate cancer (CRPC).

FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC

December 15th 2022

The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.

Dr. George on the Clinical Benefit of Phenotypic Evaluation in Prostate Cancer

December 15th 2022

Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.

European Commission Approves Pluvicto for PSMA-Positive mCRPC

December 13th 2022

The European Commission has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition, for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Practical Considerations for Sequencing Cabazitaxel in Metastatic CRPC

December 12th 2022

Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.

Overview on Metastatic CRPC and Available Treatment Options

December 12th 2022

Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC

December 9th 2022

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Pluvicto Improves rPFS in PSMA-Positive mCRPC

December 5th 2022

Treatment with lutetium Lu 177 vipivotide tetraxetan led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival following treatment with an androgen receptor pathway inhibitor in patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Enzalutamide Plus Salvage Radiation Therapy Delays PSA Progression in PSA-Recurrent High-Risk Prostate Cancer

November 30th 2022

Six months of enzalutamide monotherapy in combination with salvage radiation therapy postponed prostate-specific antigen progression compared with SRT alone in men with PSA-recurrent, high-risk prostate cancer.

MHRA Approves Darolutamide Plus ADT and Docetaxel for Metastatic HSPC

November 29th 2022

The United Kingdom’s Medicines and Healthcare products Regulatory Agency has approved darolutamide tablets in combination with androgen deprivation therapy and docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Precision Medicine Provides Continued Benefit in mCRPC

November 21st 2022

Daniel J. George, MD, discusses the clinical implications use of key trials in metastatic castration-resistant prostate cancer.

Advanced Prostate Cancer Treatment Benefits From Updated Guidelines and Adaptive Sequencing Strategies

November 19th 2022

Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing.

Technological Advances Specify Optimal Therapies in Prostate Cancer

November 16th 2022

Emerging technologies such as PSMA-PET and magnetic resonance imaging, as well as increasingly refined molecular tests, are strengthening the prostate cancer treatment landscape.

Olaparib Combo Approaches EU Approval for Select Patients With mCRPC

November 14th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib in combination with abiraterone acetate and prednisone or prednisolone for use in adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not indicated.

Dr. Antonarakis on the Benefits of Genetic Testing for Select Patients With Prostate Cancer

November 14th 2022

Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.

Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing

November 12th 2022

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.